Helix BioPharma Corp. (HBP : TSX)
Common Stock
$1.17
CAD
-0.28 (-19.31%)
Last updated: 2026-09-22
Get HBP alerts:
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
-19.31%
1 Week
-15.22%
1 Month
-40.61%
YTD
-51.25%
Key Statistics
Market Cap
$89.36M
52W High
$5.40
52W Low
$1.10
P/E Ratio
-
50 Day MA
$1.64
200 Day MA
$1.82
Beta
-0.27
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/22/2026 | $1.48 | $1.58 | $1.17 | $1.17 | $1.17 | 30,226 |
| 9/21/2026 | $1.50 | $1.50 | $1.45 | $1.45 | $1.45 | 602 |
| 9/18/2026 | $1.45 | $1.45 | $1.45 | $1.45 | $1.45 | 100 |
| 9/17/2026 | $1.54 | $1.54 | $1.40 | $1.40 | $1.40 | 452 |
| 9/16/2026 | $1.40 | $1.40 | $1.40 | $1.40 | $1.40 | 112 |
| 9/15/2026 | $1.40 | $1.53 | $1.38 | $1.38 | $1.38 | 7,248 |
| 9/14/2026 | $1.43 | $1.43 | $1.40 | $1.40 | $1.40 | 1,105 |
| 9/11/2026 | $1.56 | $1.56 | $1.43 | $1.45 | $1.45 | 3,836 |
| 9/10/2026 | $1.60 | $1.60 | $1.49 | $1.52 | $1.52 | 6,201 |
| 9/9/2026 | $1.75 | $1.75 | $1.58 | $1.63 | $1.63 | 5,473 |
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 113.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+113.7% Upside
Current Price
C$1.17
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
98.0%
Annualized
90-Day Vol
67.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.98
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.10 | C$0.79 – C$1.55 |
| 60 trading days | C$1.04 | C$0.64 – C$1.68 |
| 90 trading days | C$0.98 | C$0.54 – C$1.76 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Aug 16, 2024
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About HBP
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| MNO | Meridian Mining UK Societas | $2.30 | +22.99% |
| PYR | PyroGenesis Canada Inc. | $0.23 | +17.50% |
| CJR-B | Corus Entertainment Inc | $0.04 | +16.67% |
| ITH | International Tower Hill Mines Ltd | $4.18 | +13.90% |
| CURA | Curaleaf Holdings Inc. | $16.36 | +11.29% |
| SLT | Saltire Capital Ltd. | $3.50 | +11.11% |
| SLT-U | Saltire Capital Ltd. | $2.52 | +10.53% |
| AUMN | Golden Minerals Company | $0.32 | +10.34% |
HBP.TO news timeline
15 articles covering HBP.TO, most recent first
LatestWhat's Going On With Helix BioPharma Corp. Stock Tuesday?
September 2026
- Why Helix BioPharma Corp. stock fell yesterday
- What's Going On With Helix BioPharma Corp. Stock Monday?
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday
- Why Helix BioPharma Corp. stock is plummeting today
- Why Helix BioPharma Corp. stock plummeted yesterday
- What's Going On With Helix BioPharma Corp. Stock Thursday?
- Why Helix BioPharma Corp. stock surged yesterday
- Why Helix BioPharma Corp. stock plummeted yesterday